Preprint Article Version 2 Preserved in Portico This version is not peer-reviewed

SARS-CoV-2 S1 and N-Based Serological Assays Reveal Rapid Seroconversion and Induction of Specific Antibody Response in COVID-19 Patients

Version 1 : Received: 10 May 2020 / Approved: 11 May 2020 / Online: 11 May 2020 (04:53:31 CEST)
Version 2 : Received: 30 June 2020 / Approved: 2 July 2020 / Online: 2 July 2020 (07:19:44 CEST)

How to cite: Algaissi, A.; Alfaleh, M.A.; Hala, S.; Abujamel, T.S.; Alamri, S.; Almahboub, S.A.; Alluhaybi, K.A.; Hobani, H.I.; Alsulaiman, R.M.; Alharbi, R.H.; El-Assouli, M.; Alhabbab, R.Y.; AlSaieedi, A.A.; Abdulaal, W.H.; AL-Somali, A.A.; Alofi, F.S.; Khogeer, A.A.; Mahmoud, A.B.; Alkayyal, A.A.; Almontashiri, N.A.; Pain, A.; Hashem, A.M. SARS-CoV-2 S1 and N-Based Serological Assays Reveal Rapid Seroconversion and Induction of Specific Antibody Response in COVID-19 Patients. Preprints 2020, 2020050188. https://doi.org/10.20944/preprints202005.0188.v2 Algaissi, A.; Alfaleh, M.A.; Hala, S.; Abujamel, T.S.; Alamri, S.; Almahboub, S.A.; Alluhaybi, K.A.; Hobani, H.I.; Alsulaiman, R.M.; Alharbi, R.H.; El-Assouli, M.; Alhabbab, R.Y.; AlSaieedi, A.A.; Abdulaal, W.H.; AL-Somali, A.A.; Alofi, F.S.; Khogeer, A.A.; Mahmoud, A.B.; Alkayyal, A.A.; Almontashiri, N.A.; Pain, A.; Hashem, A.M. SARS-CoV-2 S1 and N-Based Serological Assays Reveal Rapid Seroconversion and Induction of Specific Antibody Response in COVID-19 Patients. Preprints 2020, 2020050188. https://doi.org/10.20944/preprints202005.0188.v2

Abstract

As the coronavirus disease 2019 (COVID-19), which is caused by the novel SARS-CoV-2, continues to spread rapidly around the world, there is a need for well validated serological assays that allow the detection of viral specific antibody responses in COVID-19 patients or recovered individuals. In this study, we established and used multiple indirect Enzyme Linked Immunosorbent Assay (ELISA)-based serological assays to study the antibody response in COVID-19 patients. In order to validate the assays we determined the cut off values, sensitivity and specificity of the assays using sera collected from pre-pandemic healthy controls, COVID-19 patients at different time points after disease-onset, and seropositive sera to other human coronaviruses. The developed SARS-CoV-2 S1 subunit of the spike glycoprotein and nucleocapsid (N)-based ELISAs not only showed high specificity and sensitivity but also did not show any cross-reactivity with other CoVs. We also show that all RT-PCR confirmed COVID-19 patients tested in our study developed both virus specific IgM and IgG antibodies as early as week one after disease onset. Our data also suggest that the inclusion of both S1 and N in serological testing would capture as many potential SARS-CoV-2 positive cases as possible than using any of them alone. This is specifically important for tracing contacts and cases and conducting large-scale epidemiological studies to understand the true extent of virus spread in populations.

Keywords

SARS-CoV-2 serology; ELISA; N protein; COVID-19; serosurvey

Subject

Biology and Life Sciences, Virology

Comments (1)

Comment 1
Received: 2 July 2020
Commenter: Abdullah Algaissi
Commenter's Conflict of Interests: Author
Comment: We have added more data and updated the figures. Accordingly, the title of the manuscript is now changed.
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 1
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.